Lazard Asset Management
RLAY icon

Lazard Asset Management’s Relay Therapeutics RLAY Stock Holding History

Lazard Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-818
Closed -$5K – 2499
2024
Q3 		$5K Sell
818
-60,606
-99% -$453K ﹤0.01% 2056
2024
Q2 		$400K Buy
+61,424
New +$420K ﹤0.01% 1295
2024
Q1 		– Sell
-29,669
Closed -$326K – 2326
2023
Q4 		$326K Buy
+29,669
New +$250K ﹤0.01% 1237
2021
Q2 		– Sell
-1,869
Closed -$64K – 2052
2021
Q1 		$64K Buy
+1,869
New +$81.1K ﹤0.01% 1340

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Lazard Asset Management's RLAY Position: Q4 2024 in Review

Lazard Asset Management sold out of Relay Therapeutics (RLAY) in Q4 2024, closing a stake of 818 shares — an estimated $5K sold.

Lazard Asset Management first reported a position in RLAY in Q1 2021 and held it in 4 quarters. The position peaked at $400K in Q2 2024. 199 funds tracked by Wall St. Rank hold RLAY as of Q4 2024.

  • Lazard Asset Management reported no remaining Relay Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Lazard Asset Management sold 818 Relay Therapeutics shares in Q4 2024, an estimated $5K.
  • Lazard Asset Management first reported a position in Relay Therapeutics in Q1 2021 and held it in 4 quarters.
  • Lazard Asset Management's Relay Therapeutics position peaked at $400K in Q2 2024.
  • 199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2024.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.